Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Apixaban

Apixaban

Direct oral factor Xa inhibitor (DOAC)

DOACAFVTEAdultHigh Yield

Indication

NVAF β€’ acute VTE treatment β€’ extended VTE prevention after 6 months

At a glance

INDICATIONS (CORE USE)

NVAF stroke prevention; VTE treatment and extended prophylaxis β€” **CrCl-based dose reduction**; not for mechanical mitral valve.

ADULT DOSE (STANDARD)

5 mg BID vs **2.5 mg BID** if β‰₯2 of: age β‰₯80, weight ≀60 kg, Cr β‰₯1.5; **CrCl 15–29** often 2.5 mg BID for AF

MAX DOSE

10 mg/day (5 mg BID) usual max labeled for AF; VTE acute 10 mg BID Γ— 7d then 5 mg BID β€” verify label

Route

PO

PEDIATRIC DOSE

Not established for most indications β€” pediatric trials context only

Do not miss

Must-not-miss safety points

Major warning

- **Bleeding** β€” no routine monitoring; rely on renal function, age, weight, interactions - Strong **CYP3A4 + P-gp** dual inhibitors/inducers β†’ major exposure changes β€” dose adjust or avoid - Neuraxial anesthesia β†’ ASRA timing windows

Indications

USE IF: NVAF or VTE when DOAC appropriate and CrCl allows. AVOID IF: mechanical mitral valve, moderate-severe mitral stenosis, triple-positive APS, CrCl below labeled threshold without dose rule, strong dual inhibitors.

Primary

  • Non-valvular atrial fibrillation β€” stroke prevention
  • Treatment of DVT/PE and reduction in risk of recurrence

Secondary

  • Post-hospital discharge VTE prophylaxis (surgical/medical) β€” label-specific

Dosing

STANDARD (ADULT PO)

5 mg PO BID (AF) or 10 mg BID Γ—7d then 5 mg BID (VTE initiation) β€” verify indication

ADULT DOSE

**AF:** 5 mg BID; reduce to **2.5 mg BID** if β‰₯2 of age β‰₯80, weight ≀60 kg, sCr β‰₯1.5 mg/dL. **CrCl 15–29:** often **2.5 mg BID** for AF per label. **VTE:** follow acute vs continuation tables β€” not interchangeable with AF dosing.

PEDIATRIC DOSE

Not standard of care β€” specialist.

MAX DOSE

Acute VTE 10 mg BID short course per label β€” then step down.

Practical Note

Take BID consistently; missed dose rules per label (do not double).

Warnings

Clinical warnings

  • **Major active bleeding** or **high-risk bleeding** site β†’ do not initiate until addressed; hold if bleeding develops
  • **Duplicate anticoagulation** (DOAC + warfarin + LMWH + antiplatelet) β†’ medication reconciliation every transition β€” major bleed setup
  • **Mechanical heart valves** (especially mitral) / **moderate-severe mitral stenosis** / selected APS β†’ DOACs **contraindicated or not preferred** β€” use guideline-based therapy
  • **Pregnancy / breastfeeding** β†’ DOACs generally **avoided** in pregnancy; lactation β€” agent-specific β€” **specialist**
  • Discontinue β‰₯48h before high-bleed surgery (longer if CrCl low β€” institutional)
  • Spinal/epidural hematoma risk with neuraxial block

Adverse effects

  • Bleeding
  • bruising
  • nausea
  • anemia

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • **Mechanical mitral valve / moderate–severe mitral stenosis / selected APS** β€” **DOAC label restrictions** β€” use guideline-directed alternatives
  • Active pathological bleeding
  • Lesion at high bleed risk if untreated
  • Hypersensitivity to apixaban

Drug interactions

  • **Strong CYP3A4 + P-gp inhibitor** β†’ **avoid combination** or **switch agent** per label β€” do not rely on β€œmonitor only”
  • **Moderate inhibitor/inducer** β†’ **dose table per label** or **tighter bleed surveillance**
  • **NSAID or second antiplatelet added** β†’ **reassess** if surgery within days; else **clinical bleed monitoring**
  • Strong inhibitors: ketoconazole, itraconazole, ritonavir, clarithromycin β€” avoid or reduce
  • Strong inducers: rifampin, carbamazepine, phenytoin β€” reduced efficacy
  • Other anticoagulants/antiplatelets β†’ additive bleed

Special populations

Pediatrics

Not established for most indications β€” pediatric trials context only

Pregnancy

**Pregnancy:** avoid. **

Lactation

** limited data β€” discuss risk/benefit.

Renal impairment

Dose bands at CrCl 15–29; ESRD on dialysis β€” labeled dosing exists for AF in some regions β€” verify SFDA/FDA. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl β‰₯50** β†’ standard labeled doses for AF / VTE (verify indication) - **CrCl 10–50** β†’ **15–29** band often uses reduced dose (e.g. 2.5 mg BID for AF per label) β€” **not interchangeable** with β‰₯50 dosing - **CrCl <10** / **ESRD dialysis** β†’ labeled dosing exists for some indications β€” **mandatory** label + pharmacy confirmation

Hepatic impairment

Severe hepatic impairment (Child-Pugh C) β€” contraindicated; mild-moderate caution.

Elderly

Age β‰₯80 is dose-reduction criterion; fall risk counseling.

Administration

PO with or without food; BID schedule critical.

Monitoring

  • Monitor: - **What to check + when:** **CrCl** at baseline, with **AKI/dehydration**, contrast, or new renally cleared drugs β€” before any dose-band change - **Escalation β€” bleeding:** **Hold** + severity pathway; **major** β†’ **andexanet vs 4F-PCC** per protocol β€” **not vitamin K** - **Escalation β€” elective procedure:** Hold interval per CrCl + bleed risk β€” **document last dose** for neuraxial - **Escalation β€” med rec:** Duplicate ASA + DOAC + LMWH β†’ resolve stack or explicit bleed plan - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification - Renal function at baseline and if ill; annual CrCl reasonable in elderly
  • Recheck: - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Hold dose(s) β†’ recheck **renal function** + interactions β†’ resume per label β€’ **Minor bleed:** Hold DOAC β†’ local hemostasis + **CBC** β†’ restart per bleed resolution + pharmacy β€’ **Major bleed:** **DOAC reversal pathway** β€” **4F-PCC** Β± **andexanet** (per label/protocol) + **ICU** + source control + hematology

Immediate Actions

β€’ **No bleed:** Hold β†’ hemodynamic check β†’ recheck labs/meds β†’ **no vitamin K** for anticoagulant effect β€’ **Minor bleed:** Hold β†’ pressure/packing β†’ **CBC** β†’ observe per site risk β€’ **Major bleed:** Stop DOAC β†’ ABCs β†’ type & screen β†’ **call reversal protocol** (**PCC / andexanet**) β†’ **ICU**

Antidote

**Targeted reversal agents:** **Andexanet** (where indicated) and/or **4F-PCC** per protocol β€” **vitamin K does not reverse DOAC** anticoagulation

Decontamination

β€’ **Toxic ingestion (early):** Charcoal if airway protected β€’ **Bleeding patient:** Management by **hemorrhage severity**, not decontamination alone

Escalation

β€’ **Major:** **ICU**; IR/surgery; **PCC/andexanet** per protocol β€’ **Minor:** Observe if high-risk bleed site

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

BID agent β€” **adherence** matters. β†’ Check **CrCl + age + weight** for 2.5 mg BID. β†’ Interaction screen with CYP3A4/P-gp drugs.

Clinical pearls

Switching from/to warfarin: use manufacturer overlap tables + pharmacy. Peri-op hold longer if CKD. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • Bleeding precautions
  • Procedure planning
  • Adherence (BID)

Pharmacokinetics

Oral bioavailability ~50%; partial renal (~27%) and fecal; TΒ½ ~12 h.

Mechanism of action

Selective direct factor Xa inhibitor.

Common brand names

Saudi Arabia

Eliquis, Apixaban

Global

(placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **Wrong reversal:** Acute major bleed β†’ **DOAC protocol** (andexanet vs 4F-PCC) β€” **not vitamin K** for anticoagulant effect.
  • **Renal accumulation:** CrCl drop β†’ dose band may change to **2.5 mg BID** or hold β€” recheck after illness/contrast.
  • **Duplicate therapy + adherence:** BID miss β†’ never double next dose; watch overlapping parenteral anticoagulation.
  • **Neuraxial:** Last dose β†’ procedure interval per **ASRA**; wrong timing β†’ epidural hematoma.
  • Mechanical **mitral valve** β†’ not your drug.
  • Major bleed β†’ activate reversal protocol β€” do not wait for a lab β€œlevel.”
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • Bleeding precautions
  • Procedure planning
  • Adherence (BID)